Affiliation:
1. National Serology Reference Laboratory, Fitzroy, Australia
2. World Health Organization, Geneva, Switzerland
Abstract
The markets have been flooded with hundreds of SARS-CoV-2 serology tests, and although there are many published reports on their performance, comparative reports are far fewer and tend to be limited to only a few tests. In this report, we comparatively assessed 35 rapid diagnostic tests or microtiter plate enzyme immunoassays (EIAs) using a large set of samples from individuals with a history of mild to moderate COVID-19, commensurate with the target population for serosurveillance, which included serum samples from individuals previously infected, at undetermined time periods, with other seasonal human coronaviruses, Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-1.
Funder
World Health Organization
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology
Reference21 articles.
1. Rapid roll out of SARS-CoV-2 antibody testing—a concern
2. Antibody tests for identification of current and past infection with SARS-CoV-2
3. Increasing the Efficiency of a National Laboratory Response to COVID-19: a Nationwide Multicenter Evaluation of 47 Commercial SARS-CoV-2 Immunoassays by 41 Laboratories
4. World Health Organization. 2020. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. World Health Organization, Geneva, Switzerland.
5. World Health Organization. 2020. Expression of interest—general information and timelines. World Health Organization, Geneva, Switzerland. https://www.who.int/docs/default-source/coronaviruse/eoi_general-info_timelines.pdf?sfvrsn=215a8b28_5. Accessed 30 May 2022.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献